Resources from the same session
7O - Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) in previously untreated HER2+ metastatic breast cancer (mBC): Clinical efficacy and exploratory subgroup analyses in DESTINY-Breast07
Presenter: Fabrice André
Session: Oral abstract session 1
Resources:
Abstract
Slides
Webcast
8O - First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4)
Presenter: Ewa Kalinka
Session: Oral abstract session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 7O and 8O
Presenter: Giuseppe Curigliano
Session: Oral abstract session 1
Resources:
Slides
Webcast
Q&A and discussion
Session: Oral abstract session 1
Resources:
Webcast
95O - Atezolizumab plus ipatasertib shows promise in extending survival for patients with PI3K/AKT/PTEN-altered advanced solid tumors: An exploratory analysis of the ROME trial
Presenter: Andrea Botticelli
Session: Oral abstract session 1
Resources:
Abstract
Slides
Webcast
28O - TalaCom: Phase Ib investigator-initiated trial combining talazoparib and axitinib in patients with DNA damage response mutated cancers or BRCA1/2 wildtype ovarian cancer incorporating prospective intrapatient dose titration
Presenter: Natalie Ngoi
Session: Oral abstract session 1
Resources:
Abstract
Invited Discussant 95O and 28O
Presenter: Christophe Le Tourneau
Session: Oral abstract session 1
Resources:
Slides
Webcast